New drug targets common Cancer-Causing mutation in major trial
NCT ID NCT07198321
Summary
This study is testing a new drug called GFH276 in adults with advanced cancers that have a specific genetic change called a RAS mutation. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like pancreatic, lung, and colorectal cancer. It is an early-stage trial for people who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun-Yat sen university cancer center
Guangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.